NCT07469202 2026-03-13CYTALUX Dose Extension StudyOn Target Laboratories, LLCPhase 4 Not yet recruiting106 enrolled
NCT06840002 2025-09-30A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerSuzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 1/2 Recruiting150 enrolled
NCT02317705 2022-06-21Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian CancerOn Target Laboratories, LLCPhase 2 Completed48 enrolled 10 charts
NCT03180307 2022-02-04OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian CancerOn Target Laboratories, LLCPhase 3 Completed140 enrolled 11 charts 1 FDA
NCT02223052 2020-05-12Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCelgenePhase 1 Completed89 enrolled
NCT00057720 2011-07-25TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian CancerTelikPhase 3 Completed440 enrolled